http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1481687-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_34a1977e39b9e2c5e22abc930ab240f1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-191 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 |
| filingDate | 2004-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2007-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd4171f24da01ae329b7f0f3bbf427a6 |
| publicationDate | 2007-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1481687-B1 |
| titleOfInvention | Use of multimeric ligands of the TNF family with reduced toxicity for treating cell proliferative diseases |
| abstract | Using a multimerized form of ligands of tumor necrosis factor (TNF) family (preferably FasL (RTM; TNF (ligand) superfamily member 6), CD40L (RTM; TNF (ligand) superfamily member 5), TRAIL (RTM; TNF (ligand) superfamily member 10) and APRIL (RTM; TNF (ligand) superfamily member 13)) in the preparation of a medicament for injection into a cavity of the body, for treating cell proliferation diseases, is new. ACTIVITY : Cytostatic. Bleeding mice 2, 6, 24 and 48 hours post injection (day of injection was day 0). Blood (200 Microl) was collected into an eppendorf tube containing heparin (20 Microl) and centrifugated. Plasma was collected into a new tube, and stored at -80[deg]C. Mice were divided into two groups. Group I (comparative) received phosphate buffer saline (PBS) solution. Group II (test) received Mega-FasL (RTM) (100 mu g/kg) intraperitoneally. The ALT levels (U/l) in mice for test/comparative at 2, 6, 24 and 48 hours was found to be 97+--21/75+--29, 268+--130/168+--39, 409+-- 227/95+--32 and 96+--44/55+--21, respectively; and survival at 48 hours was found to be 100%. MECHANISM OF ACTION : None given. |
| priorityDate | 2003-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 182.